LYNBROOK, N.Y., Nov. 15, 2018 /PRNewswire/ -- BioSpecifics
Technologies Corp. (NASDAQ: BSTC) a biopharmaceutical company that
originated and continues to develop collagenase-based therapies
with a first in class collagenase-based product marketed as
XIAFLEX® in the U.S. and Xiapex® in Europe, today
announced that Ron Law, Ph.D., J.D.
has been appointed as Senior Vice President of Business Development
and will be responsible for strategic partnerships, reporting
directly to Thomas L. Wegman,
President of BioSpecifics. Dr. Law has been consulting for
BioSpecifics since July 15, 2018.
Dr. Law was most recently the Chief Strategy Officer of Oramed
Pharmaceuticals Inc., where he was responsible for the development
of execution of scientific and business collaborations and
partnerships, as well as the identification of new targets and
indications for its platform oral peptide delivery technology and
pipeline expansion. Prior to that, he was a scientific consultant
in oncology at Third Coast Therapeutics, a diabetes consultant at
Doctor Evidence and a business development consultant at PharmaIN.
He also held several leadership and strategic roles at Takeda
Pharmaceuticals International, spanning U.S. Medical Affairs,
Global Medical Affairs, Corporate Strategic Planning, Global
Scientific Affairs and Intelligence, and R&D External
Innovation. He holds a Ph.D. in Molecular Biology from University of California at Los Angeles, a J.D.
from the Whittier College School of Law
and both an M.S. and B.S. in Biological Sciences from the
University of Illinois at Chicago.
"I am pleased to welcome Dr. Law to the BioSpecifics team as we
continue to look to expand our research and commercial pipeline,"
said Thomas L. Wegman, President of
BioSpecifics. "Dr. Law brings strategic business development
knowledge and a strong business background, and we look forward to
the future as we work together."
"BioSpecifics has been a resourceful and innovative company for
many years and it is with great excitement that I join the team,"
said Dr. Law. "I am excited to work on maximizing the considerable
opportunities for this company to continue to innovate, both
internally and externally."
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company
that has developed injectable collagenase for thirteen clinical
indications to date. Injectable collagenase is marketed as
XIAFLEX® in the U.S. for the treatment of Dupuytren's
contracture and Peyronie's disease by BioSpecifics' partner, Endo
International plc (Endo). XIAFLEX® is also commercialized
in Japan, Europe, Canada and Australia for
Dupuytren's contracture and for Peyronie's disease
in Canada, Europe and Australia. The CCH
research and development pipeline includes several additional
promising indications, including two Phase 3 clinical trials for
the treatment of cellulite with top-line data reported in the
fourth quarter of 2018 and a BLA submission expected in the second
half of 2019. BioSpecifics is managing the development of CCH for
the treatment of uterine fibroids and has submitted the full Phase
1 data to be presented at an upcoming medical meeting. For more
information, please visit www.biospecifics.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-appoints-ron-law-phd-jd-as-senior-vice-president-of-business-development-300751675.html
SOURCE BioSpecifics Technologies Corp.